ACRS Stock Up on Licensing Deal With Biosion for Two Immunology Drugs
Portfolio Pulse from
Aclaris Therapeutics (ACRS) stock increased following an exclusive licensing agreement with Biosion for global rights to two immunology drugs, BSI-045B and BSI-502.
November 19, 2024 | 3:30 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Aclaris Therapeutics' stock surged due to a licensing agreement with Biosion, granting them global rights to two immunology drugs, BSI-045B and BSI-502.
The licensing deal is a significant development for Aclaris, as it expands their drug portfolio in the immunology sector, likely boosting investor confidence and stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100